June 15, 2020 / 12:26 PM / 2 months ago

BRIEF-Beyondspring Reports Positive Results From Trial Of Plinabulin In Patients with Neutropenia

June 15 (Reuters) - Beyondspring Inc:

* BEYONDSPRING ANNOUNCES POSITIVE TOPLINE INTERIM RESULTS FROM PROTECTIVE-2 (STUDY 106) PHASE 3 TRIAL EVALUATING SUPERIORITY OF PLINABULIN IN COMBINATION WITH NEULASTA FOR CHEMOTHERAPY-INDUCED NEUTROPENIA PREVENTION

* BEYONDSPRING INC - MET PRIMARY ENDPOINT OF RATE OF SEVERE (GRADE 4) NEUTROPENIA PREVENTION IN FIRST CHEMOTHERAPY CYCLE

* BEYONDSPRING INC - MET KEY SECONDARY ENDPOINT OF DURATION OF SEVERE NEUTROPENIA (DSN) OF CYCLE 1

* BEYONDSPRING - MET KEY SECONDARY ENDPOINT OF DSN IN FIRST EIGHT DAYS OF CYCLE 1 (P<0.05), SUPPORTING PLINABULIN’S EARLY ONSET ACTION

* BEYONDSPRING - STUDY RESULTS SUPPORT SUPERIOR PROFILE OF PLINABULIN-NEULASTA COMBINATION VERSUS NEULASTA ALONE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below